Shares of Pfizer Inc. (NYSE:PFE) were lower 2.8% on Monday morning after the pharmaceutical company reported on Sunday that it got the primary endpoint of its breast cancer drug Palbociclib, in combination with letrozole. But experts at MKM Partners kept a neutral rating, mentioning that the result was not noteworthy. Pfizer Inc. (NYSE:PFE) shares after opening at $31.48 moved to $31.71 on last trade day and at the end of the day closed at $31.20. Company price to sales ratio in past twelve months was calculated as 3.87 and price to cash ratio as 6.16. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -2.86%.
Gilead Sciences Inc. (NASDAQ: GILD) is on watch Tuesday as one major pharmacy benefits manager (PBM) is looking to stem some of its costs. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.04% in last trading session and ended the day on $72.23. GILD return on equity ratio is recorded as 28.30% and its return on assets is 13.70%.Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 53.03%.
Merck & Co., Inc. (NYSE:MRK) provided early discoveries associated with the relation between PD-L1 Expression and the clinical outcome of its under study Anti-PD-1 Immunotherapy, MK-3475 at AACR Annual Meeting 2014. Merck & Co., Inc. (NYSE:MRK) shares moved down -1.66% in last trading session and was closed at $55.19, while trading in range of $55.03 – 56.16. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 11.14%.
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) has declared that post for the new VP for quality would be taken up by E.J. Brandreth.The synthetic vaccine manufacturer is currently busy in the development of INO-5150 vaccine for prostate cancer. Inovio Pharmaceuticals Inc (NYSEMKT:INO) weekly performance is -11.11%. On last trading day company shares ended up $2.96. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -6.30%. Analysts mean target price for the company is $4.60.